Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 145Stomach Neoplasms 22Triple Negative Breast Neoplasms 21Inflammatory Breast Neoplasms 14Carcinoma, Hepatocellular 13Esophageal Neoplasms 11Lymphoma, Large B-Cell, Diffuse 7Neoplasms 6Pancreatic Neoplasms 5Urinary Bladder Neoplasms 4Adenocarcinoma Of Esophagus 4Testicular Neoplasms 3Sarcoma 3Primary Breast Cancer 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Non-Muscle Invasive Bladder Neoplasms 3Liver Neoplasms 3Gallbladder Neoplasms 3Carcinoma, Ductal, Breast 3Breast Neoplasms, Male 3Unspecified Adult Solid Tumor, Protocol Specific 2Recurrence 2Pathologic Complete Response 2Neoplastic Cells, Circulating 2Neoplasms, Germ Cell and Embryonal 2HER2-negative Breast Cancer 2Carcinoma, Adenoid Cystic 2Breast Diseases 2pCR Rate 1Women With Primary Breast Cancer 1

Interventions

palbociclib 1Letrozole 1Fulvestrant 1Epirubicin 1Docetaxel 1Cyclophosphamide 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Hormone Receptor Positive HER-2 Negative Breast Cancer × Epirubicin × Clear all
NCT05901428 2023-06-15

TCb vs EC-T in High Risk ER+/HER2- Breast Cancer

Fudan University

Phase 3 Recruiting
1,736 enrolled
Breast

Hormone Receptor Positive HER-2 Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡